生物制药公司Ionis Pharmaceuticals, Inc（IONS）今日盘前股价大涨6.88%，主要受益于公司发布的季度业绩超出市场预期。
根据公司公布的财报，截至3月31日的季度，Ionis调整后每股亏损为0.93美元，优于分析师平均预期的1.12美元亏损。公司营收同比增长10.9%，达到1.32亿美元，同样超过了分析师预期的1.2532亿美元。尽管公司仍处于亏损状态，但亏损幅度的收窄和营收的增长显示出公司业务正在向好发展。
值得注意的是，分析师对Ionis Pharmaceuticals保持乐观态度。目前，分析师对该公司股票的平均评级为"买入"，其中17个评级为"强烈买入"或"买入"，8个为"持有"，仅1个为"卖出"或"强烈卖出"。华尔街分析师给予Ionis Pharmaceuticals未来12个月的目标价中位数为60.00美元，显示出对公司未来发展的信心。然而，投资者也应注意到，该公司今年以来的股价已下跌14.7%，反映出市场对生物科技行业的整体谨慎态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.